These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 14617784

  • 1. Sensitization of breast cancer cells to radiation by trastuzumab.
    Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z.
    Mol Cancer Ther; 2003 Nov; 2(11):1113-20. PubMed ID: 14617784
    [Abstract] [Full Text] [Related]

  • 2. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
    Le XF, Arachchige-Don AS, Mao W, Horne MC, Bast RC.
    Mol Cancer Ther; 2007 Nov; 6(11):2843-57. PubMed ID: 18025271
    [Abstract] [Full Text] [Related]

  • 3. FOXO1A is a target for HER2-overexpressing breast tumors.
    Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV.
    Cancer Res; 2010 Jul 01; 70(13):5475-85. PubMed ID: 20551062
    [Abstract] [Full Text] [Related]

  • 4. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.
    Ozbay T, Durden DL, Liu T, O'Regan RM, Nahta R.
    Cancer Chemother Pharmacol; 2010 Mar 01; 65(4):697-706. PubMed ID: 19636556
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
    Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H.
    Ann Oncol; 2010 Feb 01; 21(2):255-262. PubMed ID: 19633047
    [Abstract] [Full Text] [Related]

  • 7. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT, Metz MZ, Kane SE.
    Breast Cancer Res Treat; 2005 May 01; 91(2):187-201. PubMed ID: 15868447
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.
    Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K, Lee MH, Zhao J, Bast RC.
    Cell Cycle; 2006 Aug 01; 5(15):1654-61. PubMed ID: 16861913
    [Abstract] [Full Text] [Related]

  • 11. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
    Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI.
    Int J Radiat Oncol Biol Phys; 2004 Feb 01; 58(2):344-52. PubMed ID: 14751502
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
    Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL.
    Cancer Res; 2002 Jul 15; 62(14):4132-41. PubMed ID: 12124352
    [Abstract] [Full Text] [Related]

  • 14. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.
    Breast Cancer Res Treat; 2011 Nov 15; 130(1):29-40. PubMed ID: 21153051
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
    Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP.
    Clin Cancer Res; 2009 Jun 15; 15(12):4147-56. PubMed ID: 19509167
    [Abstract] [Full Text] [Related]

  • 17. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
    Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, Hirata K, Sato M, Sato N.
    Cancer Res; 2005 Dec 01; 65(23):11018-25. PubMed ID: 16322251
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells.
    Lu Y, Zi X, Pollak M.
    Int J Cancer; 2004 Jan 20; 108(3):334-41. PubMed ID: 14648698
    [Abstract] [Full Text] [Related]

  • 20. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
    Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S.
    Ann Oncol; 2002 Jan 20; 13(1):65-72. PubMed ID: 11863114
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.